Cure My Disease

Don't miss your cure!

 Log in / Sign up

New imaging agent aims to sharpen cancer detection

NCT ID NCT07707999

Not yet recruiting Diagnosis Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This early-phase study tests a new radioactive imaging probe that targets a protein called FAP, found on many solid tumors. The probe is used with PET or SPECT scans to see if it can better locate tumors and determine if they have spread, compared to standard FDG-PET imaging. The trial involves 20 adults with confirmed or suspected solid tumors, and aims to evaluate the probe's diagnostic accuracy, safety, and how it distributes in the body.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a novel FAP-targeted radioactive imaging probe (68Ga-FAP or 177Lu-FAP)
What this could lead to
If successful, this imaging method could help doctors more accurately detect and stage solid tumors, potentially guiding better treatment decisions.
What could go wrong
This is a very early, small study (20 people) focused on imaging accuracy, not treatment. The new probe may not prove more effective than current standard imaging.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MALIGNANT NEOPLASM

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Wuhan union hosptital

    Wuhan, Hubei, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.